Elevation Oncology, Inc. (NASDAQ: ELEV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer [Yahoo! Finance]
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
Evexta Bio appoints Shawn M. Leland as Chairman of the Board of Directors [Yahoo! Finance]
Elevation Oncology, Inc. (NASDAQ: ELEV) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $10.00 price target on the stock.